var data={"title":"Bovine lipid extract surfactant (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bovine lipid extract surfactant (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/424710?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434578\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>BLES</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434581\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Lung Surfactant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434663\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Respiratory distress:</b> <i>Rescue treatment:</i> Intratracheal: Infants: Administer 5 mL/kg/dose (equals phospholipids 135 mg/kg/dose); may repeat if needed, to a maximum of 4 doses within the first 5 days of life.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repeat dosing: The manufacturer labeling does not provide recommendations regarding an interval between dosing; however, repeat dosing at least 2 hours to 6 hours after the initial dose has been recommended (Davis 2015); alternatively, it has been recommended that surfactants usually require no more frequent dosing than every 12 hours unless the surfactant is being inactivated by an infectious process, meconium, or blood (AAP [Polin 2014]). According to the manufacturer&rsquo;s labeling, the need for repeat dosing is based on a positive response to the previous dose and increased respiratory support (ie, Fi<sub>o2</sub> increased &ge;10% than that required after initial response to previous dose). Infants exhibiting deterioration of respiratory function should be evaluated for a patent ductus arteriosus, pneumothorax, and pulmonary hemorrhage prior to retreatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49366658\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturers labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49366659\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturers labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434707\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, intratracheal [bovine derived, preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BLES: Phospholipids 27 mg/mL  (3 mL, 4 mL, 5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11236624\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434704\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intratracheal: <b>For intratracheal administration only.</b> Suction infant prior to administration. Inspect solution to verify complete mixing of the suspension (may swirl gently, but <b>DO NOT SHAKE</b>). Do not filter dose. After proper placement of ETT has been established, administer intratracheally by instillation through a #5-French feeding tube inserted into the infant's ETT. <b>Do not instill BLES down the right mainstem bronchus.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer as a single bolus dose or administer dose in up to 3 aliquots as tolerated. Each dose or aliquot is instilled over 2 to 3 seconds followed by at least 30 seconds of manual ventilation. If surfactant is slow to subside in the ETT during administration, interrupt administration and hand ventilate until the ETT is cleared before continuing; consider the possibility of a mucous plug if surfactant fails to subside. Avoid administering as a slow drip or in small aliquots as this may lead to poor distribution and uneven lung compliance.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infant should be supine for the first aliquot, than turned to the left and right for subsequent aliquots. Allow 1-2 minute recovery periods after each aliquot; oxygen saturation should be ~95% before administration of next aliquot. Following administration of one full dose, withhold suctioning for 2 hours unless clinically necessary. Regimen for repeat dosing is the same as for initial dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434583\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neonatal respiratory distress syndrome: </b> Rescue treatment of neonatal respiratory distress syndrome (NRDS)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Has not been studied in infants with birth weight &lt;380 g or &gt;4,460 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49366656\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning: </b>Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434648\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Decreased lung function (defined as decreased oxygen saturation or increased CO<sub>2</sub>) (39%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (28%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Brain disease (periventricular leukomalacia: 8%), seizure (2%), hydrocephalus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Respiratory acidosis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Pulmonary hemorrhage (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary interstitial emphysema (9%), pneumothorax (8%), apnea (2%), pneumonia (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Endotracheal intubation (complications: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acidosis, hypertension, hypoxia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434645\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Active pulmonary hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434646\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mucous plugs: Marked impairment of ventilation during or shortly after dosing may indicate mucous plugs within the endotracheal tube (ETT); suctioning prior to administration may decrease chance of ETT obstruction. Replace ETT immediately if obstruction is not removed with suctioning.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sepsis: Therapy may be associated with increased incidence of sepsis; monitor closely for signs/symptoms of sepsis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transient adverse effects: <b>[Canadian Boxed Warning]: Bovine lipid extract surfactant (BLES) may be associated with transient episodes of bradycardia and decreased oxygen saturation may occur. </b>Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For intratracheal administration only. Correct any acidosis, hypoglycemia, hypothermia, or hypotension prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring: <b>[Canadian Boxed Warning]: BLES rapidly affects oxygenation and lung compliance; hyperoxia may occur within minutes of administration.</b> Assess oxygenation closely and adjust ventilator and oxygen delivery as necessary to decrease risk of retinopathy of prematurity, overdistension of chest expansion and pulmonary air leaks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel:<b> [Canadian Boxed Warning]: Restrict use of BLES to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management and general care of premature infants</b>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298880\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434653\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15583&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49366657\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Bovine lipid extract surfactant is only indicated for use in premature infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17916778\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Bovine lipid extract surfactant is only indicated for use in premature infants. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434706\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Continuous ECG, transcutaneous O<sub>2</sub> saturation, and transcutaneous CO<sub>2</sub> should be monitored during administration; after administration, frequent arterial blood gas sampling is necessary to prevent postdosing hyperoxia and hypocarbia; tidal volume after dosing, monitor chest expansion and signs of mucous plugging of ETT.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434657\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces deficient or ineffective endogenous lung surfactant in neonates with respiratory distress syndrome (RDS). Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10434659\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Onset of action: 5 to 30 minutes; significant improvement in gas exchange and lung compliance observed within 4 hours</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    BLES (bovine lipid extract surfactant) [product monograph]. London, Ontario, Canada: BLES Biochemicals Inc; March 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bovine-lipid-extract-surfactant-united-states-not-available-drug-information/abstract-text/19668609/pubmed\" target=\"_blank\" id=\"19668609\">19668609</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis DJ, Barrington KJ, Canadian Paediatric Society Fetus and Newborn Committee, &ldquo;Recommendations for neonatal surfactant therapy,&rdquo; Paediatric Child Health, 2005 105; 10(2): 109-16. Updated Jan 30 2015. Available at: http://www.cps.ca/en/search-recherche?q=recommendations%20for%20neonatal%20surfactant%20therapy. Accessed December 12, 2015.15558604</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polin RA, Carlo WA, Committee on Fetus and Newborn, American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. <i>Pediatrics.</i> 2014;133(1):156-163.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bovine-lipid-extract-surfactant-united-states-not-available-drug-information/abstract-text/24379227/pubmed\" target=\"_blank\" id=\"24379227\">24379227</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15583 Version 66.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10434578\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10434581\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F10434663\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F49366658\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F49366659\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10434707\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11236624\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10434704\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10434583\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F49366656\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10434648\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F10434645\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F10434646\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298880\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F10434653\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F49366657\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17916778\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10434706\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10434657\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F10434659\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/15583|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}